Amgen Accrued sales incentives and allowance decreased by 170.9% to -$839.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 272.6%, from $486.00M to -$839.00M. Over 3 years (FY 2021 to FY 2024), Accrued sales incentives and allowance shows an upward trend with a 43.5% CAGR.
other_increase_decrease_in_sales_incentives_and_allowance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $101.00M | $101.00M | $101.00M | $211.50M | $211.50M | $211.50M | $211.50M | -$402.00M | $575.00M | $242.00M | $520.00M | -$316.00M | -$77.00M | $929.00M | $658.00M | $486.00M | $627.00M | $1.18B | -$839.00M |
| QoQ Change | — | +0.0% | +0.0% | +109.4% | +0.0% | +0.0% | +0.0% | -290.1% | +243.0% | -57.9% | +114.9% | -160.8% | +75.6% | >999% | -29.2% | -26.1% | +29.0% | +88.8% | -170.9% |
| YoY Change | — | — | — | — | +109.4% | +109.4% | +109.4% | -290.1% | +171.9% | +14.4% | +145.9% | +21.4% | -113.4% | +283.9% | +26.5% | +253.8% | +914.3% | +27.4% | -272.6% |